MersV1, PubMed, Checkpoint, bibRecord, 002549

Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.

Identifieur interne : 002549 ( PubMed/Checkpoint ); précédent : 002548; suivant : 002550

Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.

Auteurs : T. Mitsudomi [Japon] ; S. Suzuki ; Y. Yatabe ; M. Nishio ; M. Kuwabara ; K. Gotoh ; S. Hatooka ; M. Shinoda ; M. Suyama ; M. Ogawa ; T. Takahashi ; Y. Ariyoshi ; T. Takahashi

Source :

Journal of the National Cancer Institute [ 0027-8874 ] ; 1998.

RBID : pubmed:9790550

Descripteurs français

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Autoantibodies (blood), Blotting, Western, Carcinoma, Non-Small-Cell Lung (immunology), Carcinoma, Non-Small-Cell Lung (pathology), Carcinoma, Non-Small-Cell Lung (surgery), Cell Nucleus (metabolism), Enzyme-Linked Immunosorbent Assay, Female, Humans, Lung Neoplasms (immunology), Lung Neoplasms (pathology), Lung Neoplasms (surgery), Male, Middle Aged, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Survival Analysis, Tumor Suppressor Protein p53 (immunology), Tumor Suppressor Protein p53 (metabolism).
MESH :
- chemical , blood : Autoantibodies.
- immunology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tumor Suppressor Protein p53.
- metabolism : Cell Nucleus, Tumor Suppressor Protein p53.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- surgery : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- Adult, Aged, Aged, 80 and over, Blotting, Western, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Survival Analysis.

Abstract

The presence of autoantibodies to p53 protein has been associated with the presence of p53 (also known as TP53) gene mutations in primary tumors and with poor prognosis. This study was undertaken to determine the clinical significance of p53 autoantibodies in patients with non-small-cell lung cancer (NSCLC).

DOI: 10.1093/jnci/90.20.1563
PubMed: 9790550

Affiliations:

Japon

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002664
to stream PubMed, to step Curation: 002664

Links to Exploration step

pubmed:9790550

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.</title>
<author><name sortKey="Mitsudomi, T" sort="Mitsudomi, T" uniqKey="Mitsudomi T" first="T" last="Mitsudomi">T. Mitsudomi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya</wicri:regionArea>
<wicri:noRegion>Nagoya</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Suzuki, S" sort="Suzuki, S" uniqKey="Suzuki S" first="S" last="Suzuki">S. Suzuki</name>
</author>
<author><name sortKey="Yatabe, Y" sort="Yatabe, Y" uniqKey="Yatabe Y" first="Y" last="Yatabe">Y. Yatabe</name>
</author>
<author><name sortKey="Nishio, M" sort="Nishio, M" uniqKey="Nishio M" first="M" last="Nishio">M. Nishio</name>
</author>
<author><name sortKey="Kuwabara, M" sort="Kuwabara, M" uniqKey="Kuwabara M" first="M" last="Kuwabara">M. Kuwabara</name>
</author>
<author><name sortKey="Gotoh, K" sort="Gotoh, K" uniqKey="Gotoh K" first="K" last="Gotoh">K. Gotoh</name>
</author>
<author><name sortKey="Hatooka, S" sort="Hatooka, S" uniqKey="Hatooka S" first="S" last="Hatooka">S. Hatooka</name>
</author>
<author><name sortKey="Shinoda, M" sort="Shinoda, M" uniqKey="Shinoda M" first="M" last="Shinoda">M. Shinoda</name>
</author>
<author><name sortKey="Suyama, M" sort="Suyama, M" uniqKey="Suyama M" first="M" last="Suyama">M. Suyama</name>
</author>
<author><name sortKey="Ogawa, M" sort="Ogawa, M" uniqKey="Ogawa M" first="M" last="Ogawa">M. Ogawa</name>
</author>
<author><name sortKey="Takahashi, T" sort="Takahashi, T" uniqKey="Takahashi T" first="T" last="Takahashi">T. Takahashi</name>
</author>
<author><name sortKey="Ariyoshi, Y" sort="Ariyoshi, Y" uniqKey="Ariyoshi Y" first="Y" last="Ariyoshi">Y. Ariyoshi</name>
</author>
<author><name sortKey="Takahashi, T" sort="Takahashi, T" uniqKey="Takahashi T" first="T" last="Takahashi">T. Takahashi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9790550</idno>
<idno type="pmid">9790550</idno>
<idno type="doi">10.1093/jnci/90.20.1563</idno>
<idno type="wicri:Area/PubMed/Corpus">002664</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002664</idno>
<idno type="wicri:Area/PubMed/Curation">002664</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002664</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002549</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002549</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.</title>
<author><name sortKey="Mitsudomi, T" sort="Mitsudomi, T" uniqKey="Mitsudomi T" first="T" last="Mitsudomi">T. Mitsudomi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya</wicri:regionArea>
<wicri:noRegion>Nagoya</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Suzuki, S" sort="Suzuki, S" uniqKey="Suzuki S" first="S" last="Suzuki">S. Suzuki</name>
</author>
<author><name sortKey="Yatabe, Y" sort="Yatabe, Y" uniqKey="Yatabe Y" first="Y" last="Yatabe">Y. Yatabe</name>
</author>
<author><name sortKey="Nishio, M" sort="Nishio, M" uniqKey="Nishio M" first="M" last="Nishio">M. Nishio</name>
</author>
<author><name sortKey="Kuwabara, M" sort="Kuwabara, M" uniqKey="Kuwabara M" first="M" last="Kuwabara">M. Kuwabara</name>
</author>
<author><name sortKey="Gotoh, K" sort="Gotoh, K" uniqKey="Gotoh K" first="K" last="Gotoh">K. Gotoh</name>
</author>
<author><name sortKey="Hatooka, S" sort="Hatooka, S" uniqKey="Hatooka S" first="S" last="Hatooka">S. Hatooka</name>
</author>
<author><name sortKey="Shinoda, M" sort="Shinoda, M" uniqKey="Shinoda M" first="M" last="Shinoda">M. Shinoda</name>
</author>
<author><name sortKey="Suyama, M" sort="Suyama, M" uniqKey="Suyama M" first="M" last="Suyama">M. Suyama</name>
</author>
<author><name sortKey="Ogawa, M" sort="Ogawa, M" uniqKey="Ogawa M" first="M" last="Ogawa">M. Ogawa</name>
</author>
<author><name sortKey="Takahashi, T" sort="Takahashi, T" uniqKey="Takahashi T" first="T" last="Takahashi">T. Takahashi</name>
</author>
<author><name sortKey="Ariyoshi, Y" sort="Ariyoshi, Y" uniqKey="Ariyoshi Y" first="Y" last="Ariyoshi">Y. Ariyoshi</name>
</author>
<author><name sortKey="Takahashi, T" sort="Takahashi, T" uniqKey="Takahashi T" first="T" last="Takahashi">T. Takahashi</name>
</author>
</analytic>
<series><title level="j">Journal of the National Cancer Institute</title>
<idno type="ISSN">0027-8874</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Autoantibodies (blood)</term>
<term>Blotting, Western</term>
<term>Carcinoma, Non-Small-Cell Lung (immunology)</term>
<term>Carcinoma, Non-Small-Cell Lung (pathology)</term>
<term>Carcinoma, Non-Small-Cell Lung (surgery)</term>
<term>Cell Nucleus (metabolism)</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Female</term>
<term>Humans</term>
<term>Lung Neoplasms (immunology)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Lung Neoplasms (surgery)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
<term>Prognosis</term>
<term>Proportional Hazards Models</term>
<term>Survival Analysis</term>
<term>Tumor Suppressor Protein p53 (immunology)</term>
<term>Tumor Suppressor Protein p53 (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Autoanticorps (sang)</term>
<term>Carcinome pulmonaire non à petites cellules ()</term>
<term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire non à petites cellules (immunologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Noyau de la cellule (métabolisme)</term>
<term>Pronostic</term>
<term>Protéine p53 suppresseur de tumeur (immunologie)</term>
<term>Protéine p53 suppresseur de tumeur (métabolisme)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Technique de Western</term>
<term>Test ELISA</term>
<term>Tumeurs du poumon ()</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (immunologie)</term>
<term>Valeur prédictive des tests</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Autoantibodies</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Protéine p53 suppresseur de tumeur</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
<term>Tumor Suppressor Protein p53</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cell Nucleus</term>
<term>Tumor Suppressor Protein p53</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Noyau de la cellule</term>
<term>Protéine p53 suppresseur de tumeur</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Autoanticorps</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Blotting, Western</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
<term>Prognosis</term>
<term>Proportional Hazards Models</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Technique de Western</term>
<term>Test ELISA</term>
<term>Tumeurs du poumon</term>
<term>Valeur prédictive des tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The presence of autoantibodies to p53 protein has been associated with the presence of p53 (also known as TP53) gene mutations in primary tumors and with poor prognosis. This study was undertaken to determine the clinical significance of p53 autoantibodies in patients with non-small-cell lung cancer (NSCLC).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9790550</PMID>
<DateCompleted><Year>1998</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>05</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8874</ISSN>
<JournalIssue CitedMedium="Print"><Volume>90</Volume>
<Issue>20</Issue>
<PubDate><Year>1998</Year>
<Month>Oct</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.</ArticleTitle>
<Pagination><MedlinePgn>1563-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The presence of autoantibodies to p53 protein has been associated with the presence of p53 (also known as TP53) gene mutations in primary tumors and with poor prognosis. This study was undertaken to determine the clinical significance of p53 autoantibodies in patients with non-small-cell lung cancer (NSCLC).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We studied 188 consecutive patients with NSCLC who underwent pulmonary resection and for whom preoperative serum was available. The presence of p53 autoantibodies, detected by use of two amino-terminal and two carboxy-terminal peptides (20-30 mers) as antigens and an enzyme-linked immunosorbent assay, was related to various clinicopathologic parameters and to overexpression of p53 protein in the primary tumor. For 22 patients who had p53 autoantibodies before surgery, we also examined sera taken during postoperative follow-up. Reported P values are two-sided.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Autoantibodies to p53 protein were detected in 38 patients. Patients with squamous cell carcinoma, those with more advanced disease (stage III-IV), and those with tumors that overexpressed p53 had a significantly higher incidence of p53 autoantibodies (P = .05,.0079, and .02, respectively). In all but one of the patients with postoperative serum samples, the antibody titer declined after surgery; however, there was no relationship between clinical course and this change in antibody titer. In addition, there was no relationship between the presence of p53 autoantibodies and overall survival in 171 patients who underwent potentially curative resection (P = .28); however, 13 patients with autoantibodies to amino-terminal peptides had a worse overall survival (P = .02).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In NSCLC, the incidence of p53 autoantibodies is associated with histologic type, stage, and p53 overexpression--but not with patient survival. Our data do not support the clinical utility of p53 autoantibodies as diagnostic or prognostic markers in patients with NSCLC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitsudomi</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Suzuki</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yatabe</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nishio</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kuwabara</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gotoh</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hatooka</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shinoda</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Suyama</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ogawa</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Takahashi</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ariyoshi</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Takahashi</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year>
<Month>10</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1998</Year>
<Month>10</Month>
<Day>28</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1998</Year>
<Month>10</Month>
<Day>28</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">9790550</ArticleId>
<ArticleId IdType="doi">10.1093/jnci/90.20.1563</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><noCountry><name sortKey="Ariyoshi, Y" sort="Ariyoshi, Y" uniqKey="Ariyoshi Y" first="Y" last="Ariyoshi">Y. Ariyoshi</name>
<name sortKey="Gotoh, K" sort="Gotoh, K" uniqKey="Gotoh K" first="K" last="Gotoh">K. Gotoh</name>
<name sortKey="Hatooka, S" sort="Hatooka, S" uniqKey="Hatooka S" first="S" last="Hatooka">S. Hatooka</name>
<name sortKey="Kuwabara, M" sort="Kuwabara, M" uniqKey="Kuwabara M" first="M" last="Kuwabara">M. Kuwabara</name>
<name sortKey="Nishio, M" sort="Nishio, M" uniqKey="Nishio M" first="M" last="Nishio">M. Nishio</name>
<name sortKey="Ogawa, M" sort="Ogawa, M" uniqKey="Ogawa M" first="M" last="Ogawa">M. Ogawa</name>
<name sortKey="Shinoda, M" sort="Shinoda, M" uniqKey="Shinoda M" first="M" last="Shinoda">M. Shinoda</name>
<name sortKey="Suyama, M" sort="Suyama, M" uniqKey="Suyama M" first="M" last="Suyama">M. Suyama</name>
<name sortKey="Suzuki, S" sort="Suzuki, S" uniqKey="Suzuki S" first="S" last="Suzuki">S. Suzuki</name>
<name sortKey="Takahashi, T" sort="Takahashi, T" uniqKey="Takahashi T" first="T" last="Takahashi">T. Takahashi</name>
<name sortKey="Takahashi, T" sort="Takahashi, T" uniqKey="Takahashi T" first="T" last="Takahashi">T. Takahashi</name>
<name sortKey="Yatabe, Y" sort="Yatabe, Y" uniqKey="Yatabe Y" first="Y" last="Yatabe">Y. Yatabe</name>
</noCountry>
<country name="Japon"><noRegion><name sortKey="Mitsudomi, T" sort="Mitsudomi, T" uniqKey="Mitsudomi T" first="T" last="Mitsudomi">T. Mitsudomi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002549 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002549 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:9790550
   |texte=   Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:9790550" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.

Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki